NCT04173988View on ClinicalTrials.gov

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

October 20, 2024

Study Completion Date

July 20, 2025

Conditions
ALL, Childhood B-Cell
Interventions
GENETIC

alloCART-19

"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

DRUG

Fludarabine

Chemotherapy for lymphodepletion

Trial Locations (1)

201102

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER